Curi Bio Awarded Over $4.4M in NIH Grants to Advance Translational Science
The second initiative will deliver a novel 3D neuromuscular junction used for disease modeling and potency assays for pharmaceuticals and cosmetics.
- The second initiative will deliver a novel 3D neuromuscular junction used for disease modeling and potency assays for pharmaceuticals and cosmetics.
- These grants, the first of their kind received by Curi Bio from the National Center for Advancing Translational Sciences (NCATS), demonstrate the impact that the company's innovative 3D tissue platforms have made in developing new medicines.
- These latest awards bring the total non-dilutive funding that Curi Bio has received from the NIH to over $12 million.
- This content is solely the responsibility of Curi Bio and does not necessarily represent the official views of the National Institutes of Health.